EMEND IV POWDER FOR SOLUTION

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Sẵn có từ:

MERCK CANADA INC

Mã ATC:

A04AD

INN (Tên quốc tế):

OTHER ANTIEMETICS

Liều dùng:

115MG

Dạng dược phẩm:

POWDER FOR SOLUTION

Thành phần:

FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE) 115MG

Tuyến hành chính:

INTRAVENOUS

Các đơn vị trong gói:

115ML

Loại thuốc theo toa:

Prescription

Khu trị liệu:

NEUROKININ-1 RECEPTOR ANTAGONISTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0152547001; AHFS:

Tình trạng ủy quyền:

CANCELLED POST MARKET

Ngày ủy quyền:

2010-10-28

Đặc tính sản phẩm

_ _
_Product Monograph - EMEND_
®
_ IV _
_Page 1 of 42_
PRODUCT MONOGRAPH
PR
EMEND
®
IV
fosaprepitant for injection
115 mg fosaprepitant /vial
(as fosaprepitant dimeglumine)
Neurokinin 1 (NK
1
) receptor antagonist
MERCK FROSST CANADA LTD.
16711 Trans Canada Highway
Kirkland QC H9H 3L1
Canada
www.merckfrosst.com
Date of Revision:
March 23, 2010
SUBMISSION CONTROL NO: 135170
EMEND
®
is a Registered Trademark of Merck Sharp & Dohme Corp., a subsidiary
of
MERCK & CO., INC.
Used under license.
_ _
_Product Monograph - EMEND_
®
_ IV _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND
ADMINISTRATION..............................................................................14
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND
STABILITY..........................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL
INFORMATION...............................